CE Information and Faculty Disclosures

• TARGET AUDIENCE
  This activity is intended for medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of hepatobiliary cancers.
  
  LEARNING OBJECTIVES

  • Appreciate Phase III data leading to the FDA approvals of novel first-line treatment strategies for unresectable or metastatic hepatocellular carcinoma (HCC), and discuss how these approaches can be optimally integrated into the clinical care of patients.
  • Establish an evidence-based approach to the selection and sequencing of available therapeutic options for patients with progressive HCC.
  • Discuss the biological justification for the evaluation of immune checkpoint inhibitors for advanced biliary tract cancers, and develop strategies to optimally incorporate anti-PD-1/PD-L1 antibodies into patient care.
  • Recognize the molecular heterogeneity of cholangiocarcinoma and other biliary tract cancers, and appreciate the biological rationale for efforts to exploit documented abnormalities.
  • Assess key data sets supporting the recent FDA approvals of fibroblast growth factor receptor (FGFR) inhibitors for previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with an FGFR2 fusion or other rearrangement in order to optimally select and sequence these agents in the care of appropriately identified patients.
  • Develop an understanding of available clinical trial findings supporting the use of IDH1 inhibitors for advanced cholangiocarcinoma with an IDH1 mutation in order to determine the applicability of this strategy in current clinical practice.
  • Recall available and emerging data with investigational agents and strategies currently in clinical testing for hepatobiliary cancers, and appropriately refer eligible patients for trial participation.

  ACCREDITATION STATEMENT
  Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
  
  CREDIT DESIGNATION STATEMENT
  Research To Practice designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  
  AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
  Successful completion of this CME activity, which includes participation in the evaluation components and a short post-test, enables the participant to earn up to 1.25 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for this activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
  
  Please note, this program has been specifically designed for the following ABIM specialty: medical oncology.
  
  PRIVACY POLICY
  Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.
  
  HOW TO USE THIS CME ACTIVITY
  This CME activity consists of a video component. To receive credit, the participant should review the CME information, watch the video, complete the post-test with a score of 80% or better and fill out the Educational Assessment and Credit Form located at ResearchToPractice.com/ASCO2023/HBC/Video/CME.
  
  CONTENT VALIDATION AND DISCLOSURES
  Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
  
  FACULTY — The following faculty reported relevant financial relationships with ineligible entities:
  
  Anthony El-Khoueiry, MD
  Associate Professor of Medicine
  Associate Director for Clinical Research
  Phase I Program Director
  USC Norris Comprehensive Cancer Center
  Los Angeles, California
  
  Advisory Committee and Consulting Agreements: AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Exelixis Inc, Genentech, a member of the Roche Group, Merck, Qurient, Senti Bio, Tallac Therapeutics; Contracted Research: Astex Pharmaceuticals, AstraZeneca Pharmaceuticals LP, Auransa Inc, Fulgent.
  
  Robin K (Katie) Kelley, MD
  Professor of Clinical Medicine, Division of Hematology/Oncology
  Helen Diller Family Comprehensive Cancer Center
  University of California, San Francisco (UCSF)
  San Francisco, California
  
  Advisory Committee (Payments to Institution): Agios Pharmaceuticals Inc, AstraZeneca Pharmaceuticals LP, Exelixis Inc, Ipsen Biopharmaceuticals Inc, Merck; Consulting Agreements: Compass Therapeutics, Exact Sciences Corporation, Kinnate Biopharma, Regeneron Pharmaceuticals Inc, Tyra Biosciences; Contracted Research: Agios Pharmaceuticals Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bristol Myers Squibb, EMD Serono Inc, Exelixis Inc, Genentech, a member of the Roche Group, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Novartis, Partner Therapeutics, QED Therapeutics, Relay Therapeutics, Surface Oncology, Taiho Oncology Inc; Data and Safety Monitoring Board/Committee (Uncompensated): Genentech, a member of the Roche Group, Merck; Travel Support: AstraZeneca Pharmaceuticals LP, Merck.
  
  Prof Arndt Vogel, MD
  Managing Senior Consultant
  Department of Gastroenterology, Hepatology and Endocrinology
  Hannover Medical School
  Hannover, Germany
  
  Consulting Agreements: Amgen Inc, AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Boehringer Mannheim, Bristol Myers Squibb, BTG, Daiichi Sankyo Inc, Eisai Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Merck Sharp & Dohme LLC, Pierre Fabre, Roche Laboratories Inc, Servier Pharmaceuticals LLC, Sirtex Medical Ltd, Taiho Oncology Inc, Terumo Medical Corporation; Speaker: Advanced Accelerator Applications, Amgen Inc, AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Boehringer Mannheim, Bristol Myers Squibb, BTG, Daiichi Sankyo Inc, Eisai Inc, GlaxoSmithKline, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Jiangsu Hengrui Medicine Co Ltd, Merck Sharp & Dohme LLC, Pierre Fabre, Roche Laboratories Inc, Servier Pharmaceuticals LLC, Sirtex Medical Ltd, Taiho Oncology Inc, Terumo Medical Corporation.
  
  MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI BioPharma Corp, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Corporation, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab US Inc, Gilead Sciences Inc, Grail Inc, GSK, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Kronos Bio Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc, and Zymeworks Inc.
  
  RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.
  
  This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
  
  This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Eisai Inc, Exelixis Inc, Incyte Corporation, Jazz Pharmaceuticals Inc, Merck, Seagen Inc, and Servier Pharmaceuticals LLC.
  
  Release date: June 2023
  Expiration date: June 2024
  
  After completing the post-test, learners may download and review the answers here in order to identify further areas of study.